Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.

Bioorganic & medicinal chemistry letters - 15 Apr 2011

Makatini Maya M, Petzold Katja, Sriharsha Shimoga N, Soliman Mahmoud E S, Honarparvar Bahareh, Arvidsson Per I, Sayed Yasien, Govender Patrick, Maguire Glenn E M, Kruger Hendrik G, Govender Thavendran

Abstract excerpt

In this study, we present the first account of pentacycloundecane (PCU) peptide based HIV-protease inhibitors. The inhibitor exhibiting the highest activity made use of a natural HIV-protease substrate peptide sequence, that is, attached to the cage (PCU-EAIS). This compound showed nanomolar IC(50) activity against the resistance-prone wild type C-South African HIV-protease (C-SA) catalytic site via a norstatine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkanes
Share to Binding Sites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Catalytic Domain

Share to Computer Simulation

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to South Africa

Source

Identifiers

PMID: 21429747
DOI: 10.1016/j.bmcl.2011.02.105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.PMID 21429747Read ↗

Non-peptidic HIV protease inhibitors.Semantic proximity Read ↗

An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.Semantic proximity Read ↗

HIV Capsid is a Tractable Target for Small Molecule Therapeutic InterventionSemantic proximity Read ↗

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.Semantic proximity Read ↗

Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.Semantic proximity Read ↗

Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein.Semantic proximity Read ↗

A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potencySemantic proximity Read ↗

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.Semantic proximity Read ↗

Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.Semantic proximity Read ↗

Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.Semantic proximity Read ↗

In silico investigation of binding propensity of hematoxylin derivative and damnacanthal for their potential inhibitory effect on HIV-1 Vpr from different subtypes.Semantic proximity Read ↗

Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.